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Abstract
Advanced and undifferentiated skin squamous cell carcinomas (SCCs) exhibit aggressive growth and enhanced metastasis
capability, which is associated in mice with an expansion of the cancer stem-like cell (CSC) population and with changes in
the regulatory mechanisms that control the proliferation and invasion of these cells. Indeed, autocrine activation of PDGFRα
induces CSC invasion and promotes distant metastasis in advanced SCCs. However, the mechanisms involved in this
process were unclear. Here, we show that CSCs of mouse advanced SCCs (L-CSCs) express CXCR4 and CXCR7, both
receptors of SDF-1. PDGFRα signaling induces SDF-1 expression and secretion, and the autocrine activation of this
pathway in L-CSCs. Autocrine SDF-1/CXCR4 signaling induces L-CSC proliferation and survival, and mediates PDGFRα-
induced invasion, promoting in vivo lung metastasis. Validation of these findings in patient samples of skin SCCs shows a
strong correlation between the expression of SDF1, PDGFRA, and PDGFRB, which is upregulated, along CXCR4 in tumor
cells of advanced SCCs. Furthermore, PDGFR regulates SDF-1 expression and inhibition of SDF-1/CXCR4 and PDGFR
pathways blocks distant metastasis of human PD/S-SCCs. Our results indicate that functional crosstalk between PDGFR/
SDF-1 signaling regulates tumor cell invasion and metastasis in human and mouse advanced SCCs, and suggest that CXCR4
and/or PDGFR inhibitors could be used to block metastasis of these aggressive tumors.
Introduction
Squamous cell carcinoma (SCC) is the second most com-
mon non-melanoma skin cancer in humans, accounting for
20% of cutaneous malignancies [1, 2]. Most invasive skin
SCCs conserve epithelial differentiation traits and are con-
sidered to be well-differentiated SCCs (WD-SCCs). A
subset of SCCs show poorly differentiated features and
eventually become spindle-shaped (PD/S-SCCs), the latter
characteristic being associated with enhanced recurrence,
metastasis, and reduced patient survival [3–5]. Most skin
SCC lesions are treated by surgical excision. Although high
risk and metastatic skin SCCs are treated with adjuvant
radiotherapy or chemotherapy, the clinical benefits of these
treatments have been limited [6]. Therefore, it is important
to design targeted therapies that efficiently block the
aggressive growth and metastasis of advanced SCCs.
Mouse skin SCC cells expressing CD34 and α6-integrin,
or Sox2 are enriched in tumor-initiating or cancer stem-like
cells (CSCs) relative to the bulk of tumor cells. This cell
population is responsible for long-term SCC growth and
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metastasis [7–9]. Highly aggressive and metastatic mouse
PD/S-SCCs arise from the malignant progression of WD-
SCCs [10, 11] and during this process, the CSC population
is dramatically expanded and regulatory mechanisms con-
trolling CSC proliferation and dissemination change.
FGFR1 signaling is induced in the CSCs of advanced PD/S-
SCCs to promote aggressive growth. The PDGFRα path-
way is also activated by an autocrine way in these CSCs,
which promotes CSC invasion and enhances metastasis in
PD/S-SCCs [11]. However, the mechanisms involved in
PDGFRα-induced metastasis remain unclear.
The chemokine SDF-1 (CXCL12), which binds to G
protein-coupled receptors CXCR4 and CXCR7, plays an
important role in tumor growth and metastasis in different
tumor types [12–15]. Stromal fibroblasts and cancer cells
produce SDF-1 [16], which stimulates cancer cell pro-
liferation and is responsible for recruiting CXCR4-
expressing endothelial progenitor cells, thereby increasing
tumor angiogenesis [17, 18]. CXCR4 is expressed by CSCs
in various tumor types [19–21]. SDF-1/CXCR4 signaling
increases the self-renewal of breast and brain CSCs
[22–24], and the epithelial-to-mesenchymal transition
(EMT) program and metastasis in sarcomas, breast, pan-
creatic, colon, and liver cancer cells [24–27]. CXCR7/
RDC1 receptor is expressed by immune, endothelial, and
tumor cells and binds SDF-1 with high affinity [28].
Although CXCR7 was thought to act as a scavenger
receptor [29], it was recently demonstrated that SDF-1/
CXCR7 signaling induces CSC proliferation/survival and
EMT [30, 31], supporting growth and metastasis in different
tumor types.
SDF-1 is significantly upregulated in stromal fibroblasts
of human skin SCCs relative to normal skin [32], and
CXCR4 is upregulated in metastatic SCCs in comparison to
normal skin and non-metastatic skin carcinomas [33],
whereas CXCR7 expression is induced in 70% of patient
skin SCC samples and is associated with cancer cell sur-
vival [34]. However, the role of the SDF1/CXCR4/CXCR7
pathway in cutaneous SCCs has been unclear. Here, we
demonstrate that functional crosstalk between PDGFR/
SDF-1 pathways induces the autocrine activation of SDF-1/
CXCR4 signaling in cancer cells of mouse and human PD/
S-SCCs, which promotes distant metastasis.
Results
SDF-1 and CXCR4 expression is upregulated in
mouse advanced SCCs
To determine the relevance of SDF-1 signaling in skin SCC
growth and metastasis, we initially compared the expression
of this chemokine and Cxcr4 and Cxcr7 receptors in early
WD-SCCs and advanced PD/S-SCCs of two different
lineages of mouse skin SCC progression (OT7 and OT14).
In each of these lineages, PD/S-SCCs were generated after
the serial engraftment of their WD-SCC precursors in
immunodeficient mice [11]. We found that Sdf1 expression,
which was weakly detected in early SCCs, was upregulated
in PD/S-SCCs (Fig. 1a). In WD-SCCs, Sdf1 was expressed
by fibroblasts (Fig. 1b) and immunodetected in stromal cells
(Fig. 1c), as previously described [32, 35], whereas tumor
cells and CD45+ immune cells (deficient in T-cell in nude
immunodeficient mice) exhibited a faint or undetectable
Sdf1 expression (Fig. 1b). In contrast, SDF-1 was strongly
upregulated in tumor cells of PD/S-SCCs (Fig. 1c), reaching
similar levels to those expressed by fibroblasts (Fig. 1b).
Cxcr4 and Cxcr7 expression was upregulated in
advanced SCCs relative to WD-SCCs (Fig. 1d). An
expansion of CXCR4-expressing tumor cells was detected
by immunohistochemistry in PD/S-SCCs, as compared to
WD-SCCs (Supplementary Fig. 1A). Flow cytometry ana-
lysis showed that around 3–7% of tumor cells expressed
CXCR4 (α6-integrin+/CXCR4+ cells) in WD-SCCs, and
this frequency was significantly increased in PD/S-SCCs
(Fig. 1e, f). CXCR7+ cells were more frequent than
CXCR4-expressing cells in early and advanced SCCs
(Supplementary Fig. 1A and 1B). Accordingly, 60–70% of
tumor cells expressed CXCR7 (α6-integrin+/CXCR7+
cells) in WD-SCCs and this frequency was not significantly
increased in PD/S-SCCs (Fig. 1e, f). These results suggest
that increased levels of Cxcr7 mRNA detected in advanced
tumors may be associated with a different stromal/tumor
cells ratio in WD-SCCs and PD/S-SCCs [36, 37].
Analysis of the ligand and receptors in the CSC population
(α6-integrin+/CD34+ cells) showed that CSCs isolated from
PD/S-SCCs (L-CSCs) strongly expressed Sdf1, whereas the
expression of this chemokine was practically undetectable in
CSCs of WD-SCCs (E-CSCs) (Fig. 1g). CXCR4 was mostly
expressed by a subpopulation (5–20%) of E-CSCs (Fig. 1h, i),
whereas CXCR7 was detected in CSC and non-CSC popu-
lations, and around 50–80% of E-CSCs expressed CXCR7.
Furthermore, the percentage of CXCR4- or CXCR7-
expressing α6-integrin+/CD34+ cells was not significantly
altered in PD/S-SCCs compared with WD-SCCs (Fig. 1h, i).
Since the α6-integrin+/CD34+-CSC population is expanded
in advanced tumors (Fig. 1i; see [7, 11]), our results indicate
that the global amount of CXCR4+-CSCs was increased in
the PD/S-SCCs.
It is important to highlight that similar Sdf1 and Cxcr4
upregulation was observed in primary PD/S-SCCs (sponta-
neously developed in K14-HPV16 mice [11]) and in PD/S-
SCCs that were engrafted in syngeneic immunocompetent
mice, relative to their respective WD-SCCs (Supplementary
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Fig. 1C and 1D). SDF-1 expression was significantly
induced in tumor and stromal cells (Supplementary Fig. 1E),
and an expansion of CXCR4-expressing CSCs was detected
in PD/S-SCCs generated in immunocompetent mice (Sup-
plementary Fig. 1F–1H), indicating that SDF-1 signaling
may be activated in CSCs of advanced tumors independently
of the immune status of the mice.
Autocrine SDF-1 signaling promotes PD/S-SCC CSC
proliferation and invasion
To determine whether an autocrine SDF-1 signaling is
induced in L-CSCs, we isolated tumor cells from WD-SCCs
(WD cells) and PD/S-SCCs (PD/S cells), which were
maintained in culture. We previously demonstrated that
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these primary cultures were enriched in tumor-initiating
cells that conserved the molecular traits of parental SCC
CSCs [11]. In this regard, PD/S cells expressed and secreted
higher levels of SDF-1 than WD cells (Fig. 2a, b). In
addition, PD/S cells expressed Cxcr4 and Cxcr7, showing a
lower expression of Cxcr4 than Cxcr7 (Fig. 2c). Accord-
ingly, 40–60% of α6-integrin+/CD34+-CSCs in PD/S cell
cultures expressed CXCR7, whereas 6–16% of α6-integrin
+/CD34+-CSCs expressed CXCR4 (Fig. 2d; Supplementary
Fig. 2A and 2B), and most CXCR4+-CSCs expressed
CXCR7 (Supplementary Fig. 2C).
To determine the impact of SDF-1 signaling on pro-
liferation, PD/S cells growing in basal medium or supple-
mented with purified chemokine were treated with
AMD3100, an antagonist of CXCR4 [38]. AMD3100
treatment significantly inhibited the proliferation/survival of
PD/S cells under basal conditions, and addition of SDF-1 to
the medium did not alter or only slightly induced the pro-
liferation of PD/S cells (Fig. 2e; Supplementary Fig. 2D).
Similarly, the proliferation of PD/S cells with interfered
expression of SDF-1 (Supplementary Fig. 2E) was sig-
nificantly reduced in comparison with that of PD/S control
cells (Fig. 2f; Supplementary Fig. 2F), indicating that the
autocrine activation of SDF-1 signaling promotes PD/S cell
proliferation. The expression of Cxcr4, but not of Cxcr7,
was significantly reduced in SDF-1 knocked-down cells
(Supplementary Fig. 2G), suggesting that Cxcr4 expression
is regulated directly or indirectly by SDF-1 signaling.
PD/S cells showed in vitro a strong migration and
invasion capacity, which was associated with enhanced
distant metastasis in advanced SCCs [11]. We observed
that AMD3100 treatment as well as SDF-1 abrogation
significantly reduced the invasive capability of PD/S cells
(Fig. 2h, i). These results indicate that autocrine SDF-1
signaling promotes CSC motility and invasion, which may
consequently favor CSC dissemination and metastasis.
CXCR4 inhibition blocks distant metastasis in mouse
PD/S-SCCs
As SDF-1 signaling can be activated through CXCR4 and
CXCR7, we evaluated the role of each of these receptors in
regulating PD/S-SCC growth and metastasis. For this pur-
pose, we knocked down the expression of Cxcr4 and Cxcr7
in PD/S cells of different SCC lineages (Supplementary Fig.
3A). Abrogation of CXCR4 did not affect the expression of
Cxcr7, but did significantly reduce the expression of Sdf1
(Supplementary Fig. 3B). In contrast, CXCR7 knockdown
induced the downregulation of Cxcr4, whereas Sdf1
expression was significantly reduced only in OT7 PD/S
cells (Supplementary Fig. 3B). As OT7 cells showed a
lower level of Cxcr4 expression and a smaller percentage of
CXCR4+-CSCs than OT14 cells (Fig. 2c, d), CXCR7
knockdown may lead to an almost complete abrogation of
Cxcr4 in OT7 cells, in turn causing a significant down-
regulation of Sdf1. Therefore, these data suggest that the
expression of Cxcr4 is finely regulated by the levels of
SDF-1 and CXCR7 and, in turn, that CXCR4 regulates the
expression of the ligand.
CXCR4 knockdown significantly reduced the prolifera-
tion of PD/S cells in both lineages, whereas CXCR7
knockdown only inhibited the proliferation of OT7 PD/S
cells, in accordance with the strong downregulation of Sdf1
observed in these cells (Fig. 2g; Supplementary Fig. 3C).
In order to determine the impact of CXCR4 and CXCR7
on PD/S-SCC growth and metastasis, we engrafted sh-con-
trol, sh-CXCR4, and sh-CXCR7 PD/S cells from the OT14
lineage in immunodeficient mice. sh-CXCR4 tumors
showed a reduced percentage of α6-integrin+/CXCR4+
tumor cells, and specifically of CXCR4-expressing CSCs,
compared with sh-control tumors, whereas the percentage of
CXCR7-expressing CSCs was not affected (Supplementary
Fig. 3D–3F). In contrast to CXCR7 knocked-down tumors,
sh-CXCR4 tumors grew less than control tumors (Fig. 3a),
in accordance with the significant reduction in the percen-
tage of proliferating tumor cells observed in the CXCR4-
deficient tumors (Supplementary Fig. 3G and 3H). To
determine the impact of CXCR4 signaling on tumor growth
under an immunocompetent background, sh-control and sh-
CXCR4 PD/S cells were engrafted in syngeneic immuno-
competent mice. In contrast to that observed in immunode-
ficient mice, tumor growth was not significantly blocked
after CXCR4 abrogation (Fig. 3b; Supplementary Fig. 3I), or
Fig. 1 CSCs of mouse advanced skin SCCs express CXCR4 and
CXCR7 and up-regulate the expression of Sdf1. a, bMean (±SE) levels
of Sdf1 mRNA relative to Gapdh, as quantified by qRT-PCR in WD-
SCCs and PD/S-SCCs (three different samples per group) of OT7 and
OT14 lineages (a), and in tumor cells (α6-integrin+/CD45−/CD31−
cells), immune cells (α6-integrin−/EpCAM−/CD45+/CD31− cells), and
fibroblasts (α6-integrin−/EpCAM−/CD45−/CD31− cells) isolated from
OT14 WD-SCCs and PD/S-SCCs (two different samples per group) by
FACS-sorter (b). c Representative images of the SDF-1 immunode-
tection in paraffin sections of WD-SCCs and PD/S-SCCs of OT14
lineage. Scale bar, 100 μm. d Mean (±SE) levels of the indicated
mRNAs, relative to Gapdh, as quantified by qRT-PCR in WD-SCCs
and PD/S-SCCs (three different samples per group) of OT7 and OT14
lineages. e Representative results of quantification of the indicated cell
populations in OT14 WD-SCCs and PD/S-SCCs by flow cytometry.
Percentage of α6-integrin+/CXCR4+ and α6-integrin+/CXCR7+ cells
is indicated in each panel. fMean percentages (±SE) of cell populations
analyzed in e (3–10 different tumor samples per group). g Mean (±SE)
Sdf1 mRNA levels relative to Gapdh in E-CSCs and L-CSCs (three
different samples per group) isolated by FACS-sorter from the indi-
cated tumors. h Flow cytometry quantification of CXCR4+ and
CXCR7+ cells (red numbers) into the α6-integrin+/CD34+ CSC
population (blue numbers) of the indicated tumors. i Mean percentage
(±SE) of the indicated cell populations in WD-SCCs and PD/S-SCCs,
as quantified in h. *, significant differences between compared groups
(t-test; P ≤ 0.05). n.d. not detected
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after AMD3100 treatment (Fig. 3c), suggesting that the
effect of CXCR4 inhibition on tumor growth may be tumor
microenvironment-dependent.
Furthermore, immunodeficient mice carrying sh-CXCR4
PD/S-SCCs developed significantly less metastatic foci in
the lungs than mice carrying sh-control tumors (Fig. 3d, e),
in the absence of alterations in the tumor angiogenesis,
as indicated by the unaltered frequency of CD31+ vessels
(Fig. 3f, g) and the conserved expression of Vegfr2, a
marker of endothelial cells (Supplementary Fig. 3J). Despite
the number of metastases generated from CXCR7-interfered
PD/S-SCCs was lower than from sh-control tumors, this
Fig. 2 Autocrine SDF-1 signaling promotes L-CSC proliferation and
invasion. a Mean (±SE) of Sdf1 mRNA levels relative to Gapdh, as
quantified by qRT-PCR in in vitro growing tumor cells isolated from
WD-SCC (WD cells) and PD/S-SCCs (PD/S cells) of the indicated
tumor lineages (two different primary cell cultures per tumor type and
lineage). b SDF-1 concentration in the culture medium of the indicated
cells (two primary culture cells per group and lineage), as quantified by
ELISA assays. c Mean (±SE) Cxcr4 and Cxcr7 mRNA levels, relative
to Gapdh, in PD/S cell cultures (three samples per group) of the
indicated lineages. d Mean percentages (±SE) of CXCR4- or CXCR7-
expressing α6-integrin+/CD34+ cells (three samples per group) in PD/
S cells of OT7 and OT14 lineages, as quantified by flow cytometry.
e Cell proliferation upon SDF-1α and/or AMD3100 treatment, as
measured by MTT. Results show means (±SE) of arbitrary units of
fluorescence (a.u.f.) in treated cells relative to cells growing without
SDF-1α and inhibitor. f Proliferation kinetics (means±SE of a.u.f.
relative to day 0) of control PD/S cells (sh-control) or SDF-1 interfered
cells (sh-SDF-1.1), as measured by MTT. Representative results of
two independent assays. g Proliferation kinetics (means±SE of a.u.f.)
of control PD/S cells (sh-control) and PD/S cells with CXCR4 (sh-
CXCR4.3) or CXCR7 (sh-CXCR7.1) mRNA interference, as mea-
sured by MTT. Representative results of three independent assays.
h, i Comparison of invasion capacity (mean cell index±SE) of PD/S
cells upon control or AMD3100 treatment (h), or in SDF-1 interfered
PD/S cells (i) in x-CELLingence real-time analysis. Representative
results of two independent assays. *, significant differences between
the compared groups (t-test; P ≤ 0.05)
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difference was not significant (Fig. 3d, e) and could be
associated with the downregulation of Cxcr4 expression
induced by CXCR7 knockdown.
Similarly, CXCR4 abrogation in L-CSCs and CXCR4
pharmacological inhibition by AMD3100 treatment
significantly reduced lung metastasis development in
immunocompetent mice (Fig. 3h, i). Taken together, these
results indicate that CXCR4 inhibition blocks distant
metastasis of PD/S-SCCs, independently of the immune
status of mice.
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SDF-1 abrogation in L-CSCs inhibits distant
metastasis
To determine the impact of Sdf1 upregulation in L-CSCs on
PD/S-SCC growth and metastasis, we engrafted sh-control
and sh-SDF-1 PD/S cells in immunodeficient mice. Tumor
latency and growth kinetics were similar in sh-control and
sh-SDF-1 PD/S-SCCs (Fig. 4a; Supplementary Fig. 4A),
even though the interference of the chemokine expression in
tumor cells was maintained during tumor growth (Supple-
mentary Fig. 4B). Furthermore, a reduction in the percen-
tage of α6-integrin+/CD34+/CXCR4+ CSCs, but not of α6-
integrin+/CD34+/CXCR7+ CSCs, was observed in sh-SDF-
1 tumors, compared with sh-control tumors (Fig. 4b; Sup-
plementary Fig. 4C and 4D), in accordance with the
downregulated expression of Cxcr4 observed in sh-SDF-1-
interfered PD/S cells (Supplementary Fig. 2G).
SDF-1 abrogation dramatically reduced the development
of lung metastasis from PD/S-SCCs (Fig. 4c, d; Supple-
mentary Fig. 4E). As stroma-derived SDF-1 promotes the
recruitment of endothelial cells at tumors [39], SDF-1
interference in tumor cells might also alter tumor angio-
genesis, blocking metastasis. However, a similar density of
CD31+ vessels and Vegfr2 expression were observed in
control and SDF-1-interfered tumors (Fig. 4e–g). Metastasis
blockage was not related to the attenuation of the EMT
program, as the expression of EMT-inducer transcription
factors (Supplementary Fig. 4F) and the repressed expres-
sion of Cdh1 (E-Cadherin) (data not shown) was not altered
in sh-SDF-1 tumor cells. No changes in the expression of
SDF-1 were detected in the fibroblasts isolated from sh-
SDF-1 PD/S-SCCs, as compared with the control tumors
(Fig. 4h). These results suggest that a paracrine activation of
SDF-1 signaling or the activation of other stroma-induced
signaling pathways can support tumor cell proliferation, but
not distant metastasis.
Taken together, these results indicate that abrogation of
autocrine SDF-1 signaling reduces the migration and inva-
sion capacity of CSCs of PD/S-SCCs, blocking the devel-
opment of metastasis of these advanced tumors.
Functional PDGFRα/SDF-1 signaling crosstalk
promotes L-CSC invasion in mouse PD/S-SCCs
PDGFRα signaling promotes L-CSC invasion and PD/S-
SCC metastasis [11], so we tested whether activation of this
pathway regulates SDF-1 signaling in SCC CSCs. Flow
cytometry assays demonstrated that whereas the scarce
population of CXCR4+ WD cells did not express PDGFRα,
most PD/S cells, including CXCR4+ PD/S cells, exhibited
high levels of PDGFRα (Fig. 5a, b). PDGFRα knockdown
(Fig. 5c) significantly reduced Sdf1 expression in PD/S
cells, as determined by quantitative reverse transcriptase
PCR (RT-PCR) and enzyme-linked immunosorbent assay
(ELISA) assays (Fig. 5d, e). In turn, SDF-1 knockdown
reduced the expression of PDGFRα (Fig. 5f; Supplementary
Fig. 5A and 5B), whereas the ectopic expression of SDF-1
in PD/S cells (Supplementary Fig. 5C) further upregulated
the expression of PDGFRα (Fig. 5g, h), indicating that the
activity of each of these signaling pathways modulates the
activity of the other. In order to determine whether
PDGFRα-induced invasion of PD/S cells is mediated by
SDF-1 signaling, we compared the invasion capability of
these cells under control conditions, upon inhibition of
PDGFRα signaling by treatment with Imatinib, an inhibitor
of PDGFR, and in Imatinib-treated SDF-1α-overexpressing
PD/S cells. Our results demonstrated that whereas Imatinib
treatment significantly reduced the invasion of PD/S cells,
the ectopic expression of SDF-1 restored the invasion of
Imatinib-treated PD/S cells (Fig. 5i), indicating that
PDGFRα-induced invasion is mediated by SDF-1 signaling
in PD/S cells. Therefore, these results demonstrated that
PDGFRα and SDF-1 signaling crosstalk regulates the
invasion capability of L-CSCs and promotes metastasis
development in advanced PD/S-SCCs.
PDGFR/SDF-1 signaling crosstalk in cancer cells
promotes metastasis in human advanced SCCs
Advanced and recurrent human PD/S-SCCs of skin induce
the expression of PDGFRA/B, similarly to mouse PD/S-
SCCs [11]. To determine whether SDF1 expression is
upregulated in human PD/S-SCCs, we analyzed the
expression of this chemokine in a subset of patient WD/
MD-SCCs (G2 grade tumors) and advanced SCCs (G3-G4
grade tumors) (Supplementary Table 1). We found that
Fig. 3 CXCR4 inhibition in L-CSCs blocks mouse PD/S-SCC
metastasis. a, b Growth kinetics (means±SE of tumor size, mm3) of
control (sh-control), CXCR4 (sh-CXCR4.3), and CXCR7 knocked-
down (sh-CXCR7.1) PD/S-SCCs (eleven tumors per group) in
immunodeficient mice (a), and of sh-control and sh-CXCR4.3 PD/S-
SCCs (six and ten tumors, respectively) in syngeneic immuno-
competent mice (b). c Growth kinetics (means ± SE of tumor size,
mm3) of control and AMD3100 treated PD/S-SCCs (seven tumors per
group) growing in immunocompetent mice. d Metastatic lesions
(indicated by black arrows) in the lungs of immunodeficient mice
carrying sh-control, sh-CXCR4.3, and sh-CXCR7.1 PD/S-SCCs. Scale
bar, 200 μm. e Mean of metastatic foci (±SE) per lung section (cate-
gorized by size, mm2) in mice with the indicated PD/S-SCC types (5–6
mice per group), as determined in d. f Representative images of the
immunodetection of CD31+ vessels in sh-control, sh-CXCR4.3, and
sh-CXCR7.1 PD/S-SCCs. Scale bar, 40 μm. g Mean frequency (±SE;
3–4 tumor samples per group) of CD31+ vessels per tumor section, as
determined in f. h Metastatic lesions (indicated by black arrows) in the
lungs of immunocompetent mice carrying the sh-control and sh-
CXCR4.3 PD/S-SCCs. Scale bar, 200 μm. i Mean of metastatic foci
(±SE) per lung section (categorized by size, mm2) in mice with the
indicated PD/S-SCC types and treatments (six mice per group). *,
significant differences between the compared groups (t-test; P ≤ 0.05)
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SDF1 and CXCR4 expression was induced in human skin
SCCs at late stages of progression, whereas the expression
of CXCR7 was not significantly affected (Fig. 6a, c; Sup-
plementary Table 1). Furthermore, a high positive
correlation was observed between SDF1 and PDGFRA
or PDGFRB expression in this subset of patient tumors
(Fig. 6b). SDF-1 was mostly expressed by stromal cells of
patient WD/MD-SCCs and was strongly induced in tumor
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cells of advanced SCCs (Fig. 6d), in accordance with that
observed in mouse SCCs (Fig. 1c). A reduced population of
tumor cells expressed CXCR4 in early tumors and this
population was expanded in the patient PD/S-SCCs (Sup-
plementary Fig. 6A).
To determine the relevance of SDF-1 signaling in human
SCCs, we established primary cultures of tumor cells from a
patient WD/MD-SCC (hSCC24 cells) and from a patient
PD/S-SCC (hSCC11 cells). hSCC24 WD cells grew as
adherent cells and exhibited a typical epithelial shape,
whereas hSCC11 PD/S cells grew forming spheres (Sup-
plementary Fig. 6B). In accordance with the conserved
epithelial differentiation traits of patient WD/MD-SCCs
[11], hSCC24 WD cells expressed high levels of EpCAM
and E-cadherin epithelial markers, whereas hSCC11 PD/S
cells lost the expression of these epithelial markers and
upregulated the expression of EMT-inducer transcription
factors (Supplementary Fig. 6C and 6D). These observa-
tions indicate that the EMT program was strongly induced
in these human PD/S cells. hSCC11 PD/S cells induced the
expression and secretion of SDF-1 (Fig. 6e, f), as well as
the CXCR4 expression, as compared to hSCC24 WD cells
(Fig. 6g). Furthermore, we observed an expansion of the
α6-integrin+/CXCR4+ cell population in hSCC11 PD/S
cells (Fig. 6h), consistent with that observed by immuno-
histochemistry in patient samples. However, CXCR7
expression was significantly downregulated in hSCC11 PD/
S cells (Fig. 6g), in contrast to what was observed in mouse
PD/S cells and in other human cutaneous SCC cell lines
[34]. In this regard, whereas 89% of hSCC24 WD cells
expressed CXCR7, this population of cells was strongly
reduced in hSCC11 PD/S cells (Fig. 6h). These findings
suggest that CXCR7 expression in tumor cells may be
dependent on intrinsic features and/or the stage of pro-
gression of patient tumors. Therefore, these results indicate
that SDF-1/CXCR4 signaling is induced in tumor cells of
advanced human SCCs.
In addition, a strong upregulation of PDGFRα and
PDGFRβ was detected in hSCC11 PD/S cells (Fig. 6g;
Supplementary Fig. 6E), indicating that tumor cells from
human advanced SCCs induce PDGFR signaling. Inhibition
of PDGFR by Imatinib treatment significantly reduced the
expression of SDF1 and in turn, SDF-1 knockdown reduced
PDGFRA and PDGFRB expression in hSCC11 PD/S cells
(Fig. 6i, j). Therefore, PDGFR signaling controls SDF-1
expression and vice versa, establishing a functional cross-
talk between PDGFR/SDF-1 signaling in tumor cells of
human advanced SCCs.
CXCR4 knockdown (Supplementary Fig. 6F–6H) or
AMD3100 treatment blocked the proliferation of hSCC11
PD/S cells upon basal conditions (Fig. 7a, b). Similarly,
abrogation of SDF-1 decreased hSCC11 cell proliferation
(Fig. 7c). These findings indicate that an autocrine activa-
tion of SDF-1/CXCR4 signaling promotes proliferation of
human PD/S-SCCs cells. In accordance with previous
findings in mouse PD/S cells [11], no effect on hSCC11 cell
proliferation was observed upon PDGFR inhibition by
Imatinib treatment (Fig. 7d). However, PDGFR and
CXCR4 inhibition significantly reduced the invasion cap-
ability of hSCC11 PD/S cells (Fig. 7e, f), indicating that
activation of both signaling pathways promotes tumor cell
invasion in advanced SCCs.
To determine the impact of PDGFR/SDF-1 signaling in
human PD/S-SCC growth and metastasis, hSCC11 PD/S
cells were engrafted in immunodeficient mice and when
tumor growth was detected, mice were treated with Imatinib
or AMD3100. In addition, sh-control, sh-CXCR4, and sh-
SDF-1 hSCC11 PD/S cells were engrafted in immunodefi-
cient mice. We found that PDGFR signaling inhibition,
SDF-1 abrogation, or CXCR4 inhibition by RNA inter-
ference or AMD3100 treatment did not affect human PD/S-
SCC growth (Fig. 7g–i; Supplementary Fig. 6I). However,
inhibition of both PDGFR and SDF-1/CXCR4 signaling
pathways significantly reduced the number and size of
metastatic lesions developed in the lungs (Fig. 7j–l; Sup-
plementary Fig. 6J).
Together, these results indicate that, similarly to what is
described here for mouse advanced SCCs, PDGFR signal-
ing promotes tumor cell invasion and metastasis in human
advanced SCCs, which is mediated by the activation of
SDF-1 signaling.
Discussion
High risk and metastatic skin SCCs are occasionally treated
with radiotherapy or conventional chemotherapy, but these
treatments yield little clinical benefit [6]. Since long-term
Fig. 4 Inhibition of autocrine SDF-1 signaling in L-CSCs blocks
metastasis development. a Growth kinetics (mean ± SE of tumor size,
mm3) of SDF-1 expressing (sh-control) or SDF-1 knocked-down (sh-
SDF-1.1) PD/S-SCCs (eleven tumors per group). b Mean percentage
(±SE) of CXCR4- or CXCR7-expressing α6-integrin+/CD34+ CSCs
in the indicated tumor (7–9 samples per tumor group). c Metastatic
lesions (indicated by black arrow) in lungs of immunodeficient mice
carrying sh-control or sh-SDF-1.1 PD/S-SCCs. Scale bar, 200 μm.
d Mean of metastatic foci (±SE) per lung section (categorized by size,
mm2) in mice with the indicated PD/S-SCC types (six mice per group),
as determined in c. e Mean frequency (±SE; 4–6 samples per tumor
group) of CD31+ vessels per tumor section in sh-control and sh-SDF-
1.1 PD/S-SCCs. f Representative images of the immunodetection of
CD31+ vessels in the indicated tumors. Scale bar, 40 μm. gMean level
(±SE) of Vegfr2 mRNA, relative to Gapdh in the indicated tumors (4–
6 samples per tumor group). h Mean level (±SE) of Sdf1 mRNA in
fibroblasts of sh-SDF-1 PD/S-SCCs, relative to that detected in
fibroblasts of sh-control tumors. *, significant differences between the
compared groups (t-test; P ≤ 0.05)
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SCC growth is sustained by CSCs [7, 40], it is important to
determine mechanisms controlling the proliferation and
dissemination of this subset of tumor cells to block the
aggressive growth and metastasis associated with advanced
SCCs. Although previous studies have demonstrated that
SDF-1 signaling promotes tumor growth and metastasis in
other cancer types [22–24], the relevance of this signaling
pathway in skin SCCs as well as the mechanisms regulating
the pathway have been unknown. Here, we demonstrate that
PDGFR signaling induces SDF-1 expression and the auto-
crine activation of SDF-1/CXCR4 signaling in cancer
cells and L-CSCs, which promotes the invasion capability
of these cells and lung metastasis in mouse and human
PD/S-SCCs.
Fig. 5 PDGFRα-induced invasion in L-CSCs is mediated by SDF-1
signaling. a Representative results of the quantification by flow
cytometry of the percentage of PDGFRα+/CXCR4+ cells in WD and
PD/S cells. Percentage of each cell population is indicated. b Mean
percentage (±SE; 3–5 different cell cultures per group and lineage) of
PDGFRα+/CXCR4+ cells in the indicated cell cultures, as analyzed in
a. c Representative images of PDGFRα expression in the indicated
cells after transduction with sh-control and sh-PDGFRα lentivirus.
dMean mRNA levels (±SE) of the indicated genes in sh-PDGFRα PD/
S cells relative to sh-control PD/S cells of OT7 and OT14 tumor
lineages (three different samples per group). e Quantification of SDF-1
concentration (mean±SE) in the culture medium of the indicated PD/S
cells by ELISA assays (three samples per group). f Representative
images of PDGFRα expression in two independent samples of control
and SDF-1-interfered PD/S cells. g Mean Pdgfra mRNA levels (±SE)
in SDF-1-overexpressing PD/S cells (SDF-1) relative to control cells
(transduced with empty vector). h Representative images of PDGFRα
expression in two independent samples of control and SDF-1-
overexpressing PD/S cells (OE SDF-1). i Representative results of
the invasion capability (mean cell index ± SE) of control PD/S cells in
the absence (control DMSO) or presence of Imatinib (4 μM) (control
Imatinib) and in Imatinib-treated SDF-1-overexpressing PD/S (SDF-1
Imatinib), as measured by x-CELLingence real-time analysis. GAPDH
was used as a protein-loading control in c, f and h. *, significant
differences between the compared groups (t-test; P ≤ 0.05)
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SDF-1 is expressed by stromal fibroblasts in mouse WD-
SCCs and PD/S-SCCs, and its expression is significantly
induced in CSCs of advanced SCCs. More than 50% of L-
CSCs express CXCR7, whereas a subset of these cells
expresses both CXCR4 and CXCR7 receptors. Therefore,
SDF-1 signaling may be activated in these CXCR4/
CXCR7-expressing CSCs not only by paracrine
mechanisms, through SDF-1 secreted by the stroma fibro-
blasts, but also by autocrine mechanisms. We found that
inhibition of SDF-1 and CXCR4 in L-CSCs blocks the
in vitro proliferation of these cells upon basal conditions,
indicating that autocrine activation of SDF-1 signaling
promotes L-CSCs proliferation/survival, as previously
reported in glioblastoma CSCs [23, 41]. CXCR4
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knockdown in L-CSCs significantly reduced PD/S-SCC
growth in immunodeficient mice, but not upon a proficient
immune system, suggesting that impact of CXCR4 inhibi-
tion on tumor growth may be dependent of tumor micro-
environment. In addition, abrogation of SDF-1 in L-CSCs
had non-effect on in vivo tumor growth. One possible
explanation is that stroma-derived SDF-1 drives tumor
growth through CXCR7 and/or the remaining CXCR4
receptors of L-CSCs in SDF-1-interfered tumors. Alter-
natively, under the strong reduction of tumor cell-derived
SDF-1, other cytokines or growth factors, produced by
stromal cells, may act promoting cancer cell proliferation/
survival and the growth of SDF-1 interfered PD/S-SCCs.
Therefore, our results reveal a complex system of tumor
growth regulation, implicating not only autocrine and
paracrine SDF-1 signaling in tumor cells, but also other
pathways probably activated by stroma-derived signals
(Fig. 8).
It was proposed that constitutive expression of chemo-
kines in metastasis target tissues is essential for driving
metastasis, as CXCR4-expressing cells can home to tissues
secreting high levels of SDF-1, such as lymph nodes, bone
marrow, or lung [12]. Here, we demonstrated that SDF-1
knockdown or CXCR4 inhibition significantly reduced the
in vitro invasion capability of L-CSCs and dramatically
reduced the development of lung metastasis, independently
of the immune state of mice. Therefore, autocrine SDF-1/
CXCR4 signaling is necessary to facilitate L-CSC migration
and invasion and to promote distant metastasis (Fig. 8).
Accordingly, autocrine activation of the SDF-1 pathway
was reported in various aggressive tumor types with
enhanced distant metastasis capability [42, 43]. In addition,
ectopic expression of CXCR4 in low metastatic HNSCC
cells enables these cells to metastasize to regional lymph
nodes, but not to the distant organs [44], whereas the
ectopic overexpression of SDF-1 in CXCR4+ HNSCC and
breast cancer cells enhanced in vitro cell motility and
metastasis in lung [45, 46]. The autocrine activation of
SDF-1 signaling described here could be essential for
maintaining CXCR4 expression in L-CSCs, although in this
scenario the directional homing of these migrating cells to
SDF-1-expressing tissues may be disrupted. Furthermore, as
SDF-1/CXCR4 signaling induces tumor cell survival
(reviewed in [47]), autocrine activation of this signaling
may promote migrating cell survival during dissemination
or sustain the proliferation of these cells at the distant
tissues.
Previous reports described a functional crosstalk between
PDGFR and CXCR4 signaling, as activation of PDGFR
signaling promotes stability and phosphorylation of CXCR4
in medulloblastoma cells, inducing SDF-1/CXCR4 signaling
[48, 49]. We found that PDGFRα signaling induces SDF-1
expression, which in turn regulates the expression of
PDGFRα. It is important to highlight that normal keratino-
cytes and E-CSCs express PDGF ligands, but not PDGFR or
SDF-1, which are restricted to stroma cells [36, 50, 51]. In
contrast, L-CSCs acquire the expression of PDGFRα, allow-
ing not only the autocrine activation of this pathway [11], but
also the expression of SDF-1 and the activation of SDF-1/
CXCR4 signaling, which promote L-CSC invasion and
metastasis. Furthermore, we observed that L-CSC invasion
blockage induced by Imatinib was overridden by the ectopic
expression of SDF-1, indicating that SDF-1 mediates
PDGFRα-induced invasion and metastasis. Although inhibi-
tion of PDGFRα reduces Sdf1 expression, no significant
alterations in tumor cell proliferation or tumor growth were
observed following pharmacological or genetic inhibition of
PDGFRα in PD/S-SCCs [11], in agreement with that descri-
bed after SDF-1 knocking-down. Therefore, we suggest that
other factors or pathways support tumor growth, but not
metastasis, in the absence of PDGFRα/SDF-1 signaling
activity.
A similar functional crosstalk between PDGFR and SDF-
1 was observed in human advanced SCCs. Strong induction
of PDGFRα/β, as well as SDF-1 and CXCR4, was detected
in tumor cells of patient PD/S-SCCs, and the inhibition of
PDGFR signaling downregulated SDF-1 expression and
vice versa. An autocrine activation of SDF-1/
CXCR4 signaling promoted the in vitro proliferation and
survival of these cells, although the inhibition of this sig-
naling pathway did not affect human PD/S-SCC growth,
following a similar pattern to that here described in mouse
PD/S-SCCs growing in immunocompetent mice. However,
the inhibition of PDGFR and SDF-1/CXCR4 signaling in
Fig. 6 Functional crosstalk between PDGFR and SDF1/
CXCR4 signaling in cancer cells of human advanced SCCs. a mRNA
levels of the indicated genes relative to GAPDH (individual data and
mean ± SE) in WD/MD-SCC and PD/S-SCC patient samples. P value
(t-test) of the compared groups is indicated. b Correlation between
SDF1 and PDGFRA or PDGFRB mRNA levels in the indicated patient
samples, as determined by Pearson’s test. P value is indicated.
c mRNA levels of CXCR4 and CXCR7 (individual data and mean ±
SE) in the indicated patient samples. P value (t-test) of the compared
groups is indicated. d Representative images of the immunodetection
of SDF-1 in paraffin sections of WD/MD-SCCs and PD/S-SCCs
patient samples. Scale bar, 100 μm. e Mean (±SE) SDF1 mRNA levels
relative to GAPDH, in primary culture cells isolated from human WD/
MD-SCC (hSCC24) and PD/S-SCC (hSCC11). f Mean (±SE) of SDF-
1 concentration in the culture medium of the indicated cells, as
determined by ELISA assays. g Mean (±SE) mRNA levels of the
indicated genes, relative to GAPDH, in primary culture of hSCC24 and
hSCC11 cells. h Quantification of the indicated cell populations in
hSCC24 and hSCC11 cells by flow cytometry. Percentage of α6-
integrin+/CXCR4+ and α6-integrin+/CXCR7+ cells is indicated in
each panel. i, j Mean (±SE) of the indicated mRNA in Imatinib-treated
(4 μM for 48 h) relative to those detected in untreated (control)
hSCC11 PD/S cells (i), or in sh-SDF-1 relative to sh-control hSCC11
PD/S cells (j). *, significant differences between the compared groups
(t-test; P ≤ 0.05)
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Fig. 7 Inhibition of PDGFR and SDF1/CXCR4 signaling pathways
blocks distant metastasis in human PD/S-SCCs. a, d hSCC11 cell
proliferation after the indicated treatments, as measured by MTT.
Mean (±SE) of arbitrary units of fluorescence (a.u.f.) of treated cells
relative to cells growing without SDF-1 or AMD3100 (a), or without
PDGF or Imatinib (d). b, c Representative proliferation kinetics
(means±SE of a.u.f. relative to day 0) of control (sh-control) and
CXCR4 knocked-down (sh-CXCR4.6) hSCC11 cells (b), or of control
and SDF-1 interfered hSCC11 cells (sh-SDF-1) (c), as measured by
MTT. e, f Comparison of invasion capacity (mean cell index ± SE) of
hSCC11 PD/S cells upon control or Imatinib treatment (e), or after
AMD3100 treatment (5 μg/mL) (f) in x-CELLingence real-time
analysis. g–i Growth kinetics (mean ± SE of tumor size, mm3) of
tumors generated after engrafting in immunodeficient mice:
g hSCC11 cells, which were treated daily with vehicle (control) or
Imatinib (nine tumors per group); h sh-control and SDF-1 knocked
down (sh-SDF-1) hSCC11 cells (five tumors per group); and i sh-
control and CXCR4 knocked-down (sh-CXCR4.6) hSCC11 cells (ten
tumors per group). j–l Mean of metastatic foci (±SE) per lung section
(categorized by size, mm2) developed in: j control and Imatinib-treated
mice (six mice per group); k sh-control and sh-SDF-1 PD/S-SCCs
carrying mice (five mice per group); and l sh-control and sh-CXCR4
PD/S-SCCs carrying mice (six mice per group). *, significant differ-
ences between the compared groups (t-test; P ≤ 0.05)
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human PD/S cells significantly reduced the invasive capa-
city of these cells and lung metastases development.
Together, our results show that a functional crosstalk
between PDGFR/SDF-1 is induced in tumor cells at late
stages of mouse and human skin SCC progression, in order
to induce autocrine activation of SDF-1/CXCR4 signaling
and to promote tumor cell invasion and metastasis. There-
fore, the inhibition of PDGFR or/and SDF-1/CXCR4
pathways by currently available drugs, such as Imatinib or
AMD3100, may be a possible therapeutic strategy for
blocking metastasis development in patients with advanced
human skin SCCs.
Material and methods
Mouse models and lineages of skin SCC generation
To generate the different lineages of skin SCC progression,
small pieces (2–4 mm3) of spontaneous or DMBA/TPA-
induced tumor that were developed in K14-HPV16Tg/+ mice
(FVB/C57/Bl6 F1) [52] were engrafted in the back skin of
6-week-old male nude mice (Athymic Nude-Foxn1nu;
Harlan Laboratories). Each orthotopic tumor (OT-SCC) was
serially engrafted in a new immunodeficient mouse, as
previously described [11]. Animal housing, handling, and
all procedures involving mice were approved by the
Bellvitge Biomedical Research Institute (IDIBELL) ethics
committee, in accordance with Spanish national regulations.
Human skin SCC samples
Samples of human skin SCCs were supplied by the Plastic
Surgery and Pathology Units of the Hospital Universitario
de Bellvitge (IDIBELL) and the Spanish Hospital Platform
Biobank Network (RetBioH; www.redbiobancos.es). The
protocol of sample collection was supervised and approved
by the Ethical Committee of Clinical Research of Hospital
Universitario de Bellvitge (IDIBELL). All patients were
informed beforehand and their signed consent to participate
was obtained.
SCC cell isolation and flow cytometry analysis
Tumor cells from skin SCCs were analyzed by flow cyto-
metry, and specific cell populations were isolated by FACS-
sorter, as described in Supplementary Methods.
Cell cultures
Tumor cells (hematopoietic lineage and endothelial-
negative cells) isolated from mouse WD-SCCs (WD cells)
and PD/S-SCCs (PD/S cells) from different lineages, and
tumor cells isolated from human PD/S-SCCs
Fig. 8 Impact of PDGFR/SDF-1 signaling crosstalk on PD/S-SCC
growth and distant metastasis. Our results indicate that autocrine
PDGFRα signaling (orange arrow) induces the expression of SDF-1
(blue arrow) and the autocrine activation of CXCR4/CXCR7 signaling
in L-CSCs (red arrows). Fibroblast and stroma-derived SDF-1 can also
activate this signaling pathway by a paracrine way (black arrows).
Autocrine SDF-1/CXCR4 signaling promotes L-CSC invasion,
promoting distant metastasis development. PD/S-SCCs growth may be
promoted by the activation of SDF-1/CXCR4 pathway through auto-
crine or paracrine mechanisms, but also by alternative pathways,
which can be activated by stroma-derived factors in response to
PDGFR/SDF-1 signaling inhibition. This model shows mouse SCC
findings, but can be also applied in human advanced SCCs
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(hSCC11 cells) (see Supplementary Methods for detailed
protocol) were grown in DMEM-F12 medium (GIBCO Life
Technologies) with 1× B27 (GIBCO Life Technologies)
and penicillin/streptomycin (PAA Laboratories) (basic
medium). Tumor cells isolated from human WD/MD-SCCs
(hSCC24 cells) were grown in basic medium supplemented
with EGF (20 ng/mL; Sigma). Cells were cultured at 37 °C
in a humidified, 5% CO2 incubator. Protocols for analyzing
cell proliferation and for cell transduction are described in
detail in the Supplementary Methods.
In vitro invasion assay
To test the invasion capability of human and mouse tumor
cells in response to inhibitor treatments, CIM-16 plates
(ACEA Biosciences) coated with 5% Matrigel (Factor-
Reduced; BD Biosciences) were used. PD/S cells were
previously treated without (control) or with AMD3100 (1
and 5 μg/mL; Chemscene LLC) and Imatinib (4 μM; LC
Laboratories) for 48 h, and cells (8 × 105, 4–6 replicates for
sample) were seeded in the top chamber, and placed in the
xCeLLigence system, maintaining the same concentration
of inhibitors in the lower chamber. Each assay was per-
formed twice. The cell index represents the cell invasion
capacity.
ELISA assay
To carry out these analyses, 1.5 × 106 of mouse and human
WD and PD/S cells were incubated for 48 h at 37 °C in
basic medium. The medium was then collected and cen-
trifuged (13,000 r.p.m.) for 10 min and SDF-1 concentration
in the supernatant was analyzed using the PeproTech
ELISA kit (Mini ABTS ELISA Development kit) (three
replicates per sample), following the manufacturer’s
recommendations. Substrate solution (TMB Liquid Sub-
strate) was added and incubated for 20 min at room tem-
perature. The absorbance was measured at 450 nm.
Tumor cell grafting and in vivo treatments
Sdf1, Cxcr4, and Cxcr7 expression and tumor cell populations
expressing these receptors were analyzed in skin SCCs
spontaneously developed in male and female K14-HPV16Tg/+
mice (four samples per group), and in WD-SCCs and PD/S-
SCCs generated after subcutaneous engrafting WD cells (1 ×
106 cells) and PD/S cells (1 × 104 cells) from OT7 and OT14
lineages with Matrigel (1:1; BD Biosciences) in syngeneic
immunocompetent mice (6-week-old C57Bl6/FVB F1 male
mice; four samples for group). The impact of CXCR4,
CXCR7, SDF1 knockdown on mouse tumor growth and
metastasis was studied by subcutaneously co-injecting 4 × 103
sh-control (n= 10), sh-CXCR4 (n= 11), sh-CXCR7 (n= 11),
and sh-SDF1 (n= 11) mouse PD/S cells with Matrigel (1:1;
BD Biosciences) in 6-week-old male nude mice. Following
the same protocol, 4 × 103 sh-control (n= 6) and sh-CXCR4
(n= 10) PD/S cells were injected in immunocompetent mice.
To test the in vivo effect of CXCR4 and SDF1 knockdown on
human PD/S-SCC growth and metastasis, 1 × 106 of sh-
control (n= 15), sh-CXCR4 (n= 10), and sh-SDF1 (n= 5)
hSCC11 cells were engrafted in NOD-scid IL2Rgnull (NSG)
mice. Tumor growth was monitored and tumors were excised
after 25–27 days (mouse SCCs) or 30–32 days (human SCCs),
when they reached a critical size. Mice were sacrificed 20 days
(mouse PD/S-SCCs) or 10 days (human PD/S-SCCs) after
tumor resection. The lungs were recovered and formalin-fixed
to quantify the metastatic lesions (5–6 samples per group).
For pharmacological inhibition of CXCR4 in mouse PD/
S-SCCs, 4 × 103 OT14 PD/S cells were subcutaneously
engrafted in syngeneic immunocompetent mice. For phar-
macological inhibition of PDGFR and CXCR4 in human
PD/S-SCCs, 1 × 106 of hSCC11 cells were engrafted in
NSG mice. When the tumors were palpable, mice were
randomly distributed between control and treated groups, in
order that tumor size was similar in both groups at the start
of the treatment. Then, mice were intraperitoneally treated
with AMD3100 (Glentham Life Sciences; 15 mg/kg; diluted
in sterile serum), or serum (n= 7 tumors per group for
mouse and human SCCs), or orally administered with
Imatinib (LC Laboratories; 150 mg/kg; diluted in water) or
water (n= 9 tumors per group), daily. Tumors were excised
when they reached a critical size (20 days post-engraftment)
and mice continued to be treated until sacrifice, 10–15 days
(for human SCCs) or 20 days (for mouse SCCs) after tumor
resection. Then, lungs were recovered and formalin-fixed to
quantify the development of the metastatic lesions
(5–6 samples per group). Tumors that did not grow after
4–5 weeks of the engraftment or mice that died before the
experiment endpoint were excluded.
Histology, immunohistochemistry, and western blot
assays
Tumor and lung samples were fixed in 4% formaldehyde
overnight at 4 °C, paraffin-embedded, and sectioned at
4 μm. For histopathological analysis and quantification of
metastatic lesions, tumor and lung sections were stained
with hematoxylin and eosin. Protocols for immuno-
fluorescence assays and western blot analysis are described
in detail in the Supplementary Methods.
Reverse transcription and quantitative real-time
PCR
Total RNA was extracted from tumors and cells using
Trizol Reagent (Invitrogen). Reverse transcription reactions
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and quantitative real-time PCR were carried out as descri-
bed in Supplementary Methods.
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